Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia
- PMID: 30889571
- DOI: 10.1159/000499694
Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia
Abstract
An appropriate diagnostic evaluation is essential for the most appropriate treatment to be performed. Currently, macroprolactinemia is the third most frequent cause of nonphysiological hyperprolactinemia after drugs and prolactinomas. Up to 40% of macroprolactinemic patients may present with hypogonadism symptoms, infertility, and/or galactorrhea. Thus, the screening for macroprolactin is indicated not only for asymptomatic subjects but also for those without an obvious cause for their prolactin (PRL) elevation. Before submitting patients to macroprolactin screening and pituitary magnetic resonance imaging, one should rule out pregnancy, drug-induced hyperprolactinemia, primary hypothyroidism, and renal failure. The magnitude of PRL elevation can be useful in determining the etiology of hyperprolactinemia. PRL values >250 ng/mL are highly suggestive of prolactinomas and virtually exclude nonfunctioning pituitary adenomas (NFPAs) and other sellar masses as the etiology of hyperprolactinemia. However, they can also be found in subjects with macroprolactinemia, drug-induced hyper-prolactinemia or chronic renal failure. By contrast, most patients with NFPAs, drug-induced hyperprolactinemia, macroprolactinemia, or systemic diseases present with PRL levels <100 ng/mL. However, exceptions to these rules are not rare. Indeed, up to 25% of patients harboring a microprolactinoma or a cystic macroprolactinoma may also have PRL <100 ng/mL. Falsely low PRL levels may result from the so-called "hook effect," which should be considered in all cases of large (≥3 cm) pituitary adenomas associated with normal or mildly elevated PRL levels (≤250 ng/mL). The hook effect may be unmasked by repeating PRL measurement after a 1:100 serum sample dilution.
Keywords: Hyperprolactinemia; Macroprolactinemia; Pitfalls; Prolactin.
© 2019 S. Karger AG, Basel.
Similar articles
-
Challenges and pitfalls in the diagnosis of hyperprolactinemia.Arq Bras Endocrinol Metabol. 2014 Feb;58(1):9-22. doi: 10.1590/0004-2730000003002. Arq Bras Endocrinol Metabol. 2014. PMID: 24728159 Review.
-
Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.Arch Endocrinol Metab. 2018 Mar-Apr;62(2):236-263. doi: 10.20945/2359-3997000000032. Arch Endocrinol Metab. 2018. PMID: 29768629 Free PMC article. Review.
-
Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.Minerva Endocrinol. 2007 Jun;32(2):79-86. Minerva Endocrinol. 2007. PMID: 17557033
-
Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia.Taiwan J Obstet Gynecol. 2017 Dec;56(6):719-724. doi: 10.1016/j.tjog.2017.10.002. Taiwan J Obstet Gynecol. 2017. PMID: 29241908 Review.
-
[Prevalence of macroprolactinemia among 115 patients with hyperprolactinemia].Arq Bras Endocrinol Metabol. 2007 Feb;51(1):86-91. doi: 10.1590/s0004-27302007000100014. Arq Bras Endocrinol Metabol. 2007. PMID: 17435860 Portuguese.
Cited by
-
Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.Eur J Endocrinol. 2022 Feb 3;186(3):P1-P33. doi: 10.1530/EJE-21-0977. Eur J Endocrinol. 2022. PMID: 35000899 Free PMC article.
-
Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.Front Endocrinol (Lausanne). 2024 Feb 2;15:1338345. doi: 10.3389/fendo.2024.1338345. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38370355 Free PMC article. Review.
-
Prolactin response to antipsychotics: An inpatient study.PLoS One. 2020 Feb 4;15(2):e0228648. doi: 10.1371/journal.pone.0228648. eCollection 2020. PLoS One. 2020. PMID: 32017792 Free PMC article.
-
Diagnosis of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM).Arch Endocrinol Metab. 2024 Apr 5;68:e230502. doi: 10.20945/2359-4292-2023-0502. Arch Endocrinol Metab. 2024. PMID: 38578472 Free PMC article.
-
Current Insights in Prolactin Signaling and Ovulatory Function.Int J Mol Sci. 2024 Feb 6;25(4):1976. doi: 10.3390/ijms25041976. Int J Mol Sci. 2024. PMID: 38396659 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources